CClinicalTrials.gg
Sign In
CompletedNCT05292261H4HWUpdated Apr 6, 2022

Effects of a Recreational Team Handball-based Programme on Health and Physical Fitness of Postmenopausal Women

An interventional study of Recreational team handball in Menopause, sponsored by University Institute of Maia. Completed at 1 site in Portugal. Open to female participants. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by University Institute of Maia · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 6 years 2 months after the study started (first participant enrolled Jan 2016, registered Mar 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Sex
Female
01

Study summary

This study aimed at determining the short- (16 weeks) and long-term (36 weeks) health and physical fitness effects and adherence of recreational team handball training for postmenopausal women without previous experience with the sport.

The investigators hypothesized that short-term recreational team handball training would result in positive health and physical fitness adaptations and that the health and physical fitness improvements achieved after the first 16 weeks would be maintained or further improved at the long-term. Moreover, the investigators also hypothesized that the adherence to this exercise mode would be maintained throughout the 36 weeks (long-term) compared to the first 16 weeks (short-term).

02

Conditions studied

  • Menopause
03

In context

Lead sponsor

University Institute of Maia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Inactive postmenopausal women aged +55 years or younger if with menopause for at least 3 years

Exclusion criteria

Exclusion Criteria:

  • Any medical contraindications to perform moderate-to-vigorous physical activity
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Team handball group

    The team handball group participants were encouraged to performed at least two out of three weekly supervised team handball training sessions of 60 min each, for 36 weeks.

    Other: Recreational team handball

  • No intervention
    Control group

    The control group participants were instructed to keep their regular daily physical activity for 36 weeks.

Interventions

  • OtherRecreational team handball

    Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.

06

What researchers measure

Primary outcomes

  1. Between group differences in peak oxygen uptake at week 16

    Determined by pulmonary gas exchange measurements, during an incremental treadmill test until voluntary exhaustion.

    Time frame: Week 16

  2. Between group differences in peak oxygen uptake at week 36

    Determined by pulmonary gas exchange measurements, during an incremental treadmill test until voluntary exhaustion.

    Time frame: Week 36

  3. Changes from baseline in peak oxygen uptake at week 16

    Determined by pulmonary gas exchange measurements, during an incremental treadmill test until voluntary exhaustion.

    Time frame: Baseline and week 16

  4. Changes from baseline in peak oxygen uptake at week 36

    Determined by pulmonary gas exchange measurements, during an incremental treadmill test until voluntary exhaustion.

    Time frame: Baseline and week 36

  5. Changes from week 16 in peak oxygen uptake at week 36

    Determined by pulmonary gas exchange measurements, during an incremental treadmill test until voluntary exhaustion.

    Time frame: Week 16 and week 36

Secondary outcomes

  1. Between group differences in resting heart rate at week 16

    Determined by an automatic upper arm blood pressure monitor according to standardized procedures.

    Time frame: Week 16

  2. Between group differences in resting heart rate at week 36

    Determined by an automatic upper arm blood pressure monitor according to standardized procedures.

    Time frame: Week 36

  3. Changes from baseline in resting heart rate at week 16

    Determined by an automatic upper arm blood pressure monitor according to standardized procedures.

    Time frame: Baseline and week 16

  4. Changes from baseline in resting heart rate at week 36

    Determined by an automatic upper arm blood pressure monitor according to standardized procedures.

    Time frame: Baseline and week 36

  5. Changes from week 16 in resting heart rate at week 36

    Determined by an automatic upper arm blood pressure monitor according to standardized procedures.

    Time frame: Week 16 and week 36

  6. Between group differences in body mass at week 16

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 16

  7. Between group differences in body mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 36

  8. Changes from baseline in body mass at week 16

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Baseline and week 16

  9. Changes from baseline in body mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Baseline and week 36

  10. Changes from week 16 in body mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 16 and week 36

  11. Between group differences in fat mass at week 16

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 16

  12. Between group differences in fat mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 36

  13. Changes from baseline in fat mass at week 16

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Baseline and week 16

  14. Changes from baseline in fat mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Baseline and week 36

  15. Changes from week 16 in fat mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 16 and week 36

  16. Between group differences in lean mass at week 16

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 16

  17. Between group differences in lean mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 36

  18. Changes from baseline in lean mass at week 16

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Baseline and week 16

  19. Changes from baseline in lean mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Baseline and week 36

  20. Changes from week 16 in lean mass at week 36

    Determined by whole-body dual- energy X-ray absorptiometry following standard procedures.

    Time frame: Week 16 and week 36

  21. Between group differences in lumbar spine bone mineral density at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16

  22. Between group differences in lumbar spine bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 36

  23. Changes from baseline in lumbar spine bone mineral density at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 16

  24. Changes from baseline in lumbar spine bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 36

  25. Changes from week 16 in lumbar spine bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16 and week 36

  26. Between group differences in dominant femur bone mineral density at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16

  27. Between group differences in dominant femur bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 36

  28. Changes from baseline in dominant femur bone mineral density at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 16

  29. Changes from baseline in dominant femur bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 36

  30. Changes from week 16 in dominant femur bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16 and week 36

  31. Between group differences in dominant femoral neck bone mineral density at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16

  32. Between group differences in dominant femoral neck bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 36

  33. Changes from baseline in dominant femoral neck bone mineral density at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 16

  34. Changes from baseline in dominant femoral neck bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 36

  35. Changes from week 16 in dominant femoral neck bone mineral density at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16 and week 36

  36. Between group differences in lumbar spine bone mineral content at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16

  37. Between group differences in lumbar spine bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 36

  38. Changes from baseline in lumbar spine bone mineral content at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 16

  39. Changes from baseline in lumbar spine bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 36

  40. Changes from week 16 in lumbar spine bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16 and week 36

  41. Between group differences in dominant femur bone mineral content at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16

  42. Between group differences in dominant femur bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 36

  43. Changes from baseline in dominant femur bone mineral content at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 16

  44. Changes from baseline in dominant femur bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 36

  45. Changes from week 16 in dominant femur bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16 and week 36

  46. Between group differences in dominant femoral neck bone mineral content at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16

  47. Between group differences in dominant femoral neck bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 36

  48. Changes from baseline in dominant femoral neck bone mineral content at week 16

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 16

  49. Changes from baseline in dominant femoral neck bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Baseline and week 36

  50. Changes from week 16 in dominant femoral neck bone mineral content at week 36

    Determined by dual- energy X-ray absorptiometry regional scans following standard procedures.

    Time frame: Week 16 and week 36

  51. Between group differences in osteocalcin at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16

  52. Between group differences in osteocalcin at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 36

  53. Changes from baseline in osteocalcin at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 16

  54. Changes from baseline in osteocalcin at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 36

  55. Changes from week 16 in osteocalcin at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16 and week 36

  56. Between group differences in procollagen type-1 amino-terminal propeptide at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16

  57. Between group differences in procollagen type-1 amino-terminal propeptide at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 36

  58. Changes from baseline in procollagen type-1 amino-terminal propeptide at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 16

  59. Changes from baseline in procollagen type-1 amino-terminal propeptide at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 36

  60. Changes from week 16 in procollagen type-1 amino-terminal propeptide at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16 and week 36

  61. Between group differences in carboxy-terminal type-1 collagen crosslinks at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16

  62. Between group differences in carboxy-terminal type-1 collagen crosslinks at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 36

  63. Changes from baseline in carboxy-terminal type-1 collagen crosslinks at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 16

  64. Changes from baseline in carboxy-terminal type-1 collagen crosslinks at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 36

  65. Changes from week 16 in carboxy-terminal type-1 collagen crosslinks at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16 and week 36

  66. Between group differences in sclerostin at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16

  67. Between group differences in sclerostin at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 36

  68. Changes from baseline in sclerostin at week 16

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 16

  69. Changes from baseline in sclerostin at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Baseline and week 36

  70. Changes from week 16 in sclerostin at week 36

    Determined by chemiluminescence method using a fully automated immunoassay system.

    Time frame: Week 16 and week 36

  71. Between group differences in isometric knee extension peak torque at week 16

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Week 16

  72. Between group differences in isometric knee extension peak torque at week 36

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Week 36

  73. Changes from baseline in isometric knee extension peak torque at week 16

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Baseline and week 16

  74. Changes from baseline in isometric knee extension peak torque at week 36

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Baseline and week 36

  75. Changes from week 16 in isometric knee extension peak torque at week 36

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Week 16 and week 36

  76. Between group differences in isometric knee extension rate of force development at week 16

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Week 16

  77. Between group differences in isometric knee extension rate of force development at week 36

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Week 36

  78. Changes from baseline in isometric knee extension rate of force development at week 16

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Baseline and week 16

  79. Changes from baseline in isometric knee extension rate of force development at week 36

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Baseline and week 36

  80. Changes from week 16 in isometric knee extension rate of force development at week 36

    Determined by a Biodex isokinetic dynamometer, during a isometric knee extension contraction

    Time frame: Week 16 and week 36

  81. Between group differences in upper body strength at week 16

    Determined by a handgrip dynamometer.

    Time frame: Week 16

  82. Between group differences in upper body strength at week 36

    Determined by a handgrip dynamometer.

    Time frame: Week 36

  83. Changes from baseline in upper body strength at week 16

    Determined by a handgrip dynamometer.

    Time frame: Baseline and week 16

  84. Changes from baseline in upper body strength at week 36

    Determined by a handgrip dynamometer.

    Time frame: Baseline and week 36

  85. Changes from week 16 in upper body strength at week 36

    Determined by a handgrip dynamometer.

    Time frame: Week 16 and week 36

  86. Between group differences in postural balance at week 16

    Determined by the number of falls in a single-legged flamingo balance test.

    Time frame: Week 16

  87. Between group differences in postural balance at week 36

    Determined by the number of falls in a single-legged flamingo balance test.

    Time frame: Week 36

  88. Changes from baseline in postural balance at week 16

    Determined by the number of falls in a single-legged flamingo balance test.

    Time frame: Baseline and week 16

  89. Changes from baseline in postural balance at week 36

    Determined by the number of falls in a single-legged flamingo balance test.

    Time frame: Baseline and week 36

  90. Changes from week 16 in postural balance at week 36

    Determined by the number of falls in a single-legged flamingo balance test.

    Time frame: Week 16 and week 36

  91. Between group differences in aerobic performance at week 16

    Determined by meters covered in the Yo-Yo intermittent endurance level 1 test.

    Time frame: Week 16

  92. Between group differences in aerobic performance at week 36

    Determined by meters covered in the Yo-Yo intermittent endurance level 1 test.

    Time frame: Week 36

  93. Changes from baseline in aerobic performance at week 16

    Determined by meters covered in the Yo-Yo intermittent endurance level 1 test.

    Time frame: Baseline and week 16

  94. Changes from baseline in aerobic performance at week 36

    Determined by meters covered in the Yo-Yo intermittent endurance level 1 test.

    Time frame: Baseline and week 36

  95. Changes from week 16 in aerobic performance at week 36

    Determined by meters covered in the Yo-Yo intermittent endurance level 1 test.

    Time frame: Week 16 and week 36

  96. Between group differences in total cholesterol at week 16

    Determined by an automated analyser.

    Time frame: Week 16

  97. Between group differences in total cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Week 36

  98. Changes from baseline in total cholesterol at week 16

    Determined by an automated analyser.

    Time frame: Baseline and week 16

  99. Changes from baseline in total cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Baseline and week 36

  100. Changes from week 16 in total cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Week 16 and week 36

  101. Between group differences in high-density lipoprotein cholesterol at week 16

    Determined by an automated analyser.

    Time frame: Week 16

  102. Between group differences in high-density lipoprotein cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Week 36

  103. Changes from baseline in high-density lipoprotein cholesterol at week 16

    Determined by an automated analyser.

    Time frame: Baseline and week 16

  104. Changes from baseline in high-density lipoprotein cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Baseline and week 36

  105. Changes from week 16 in high-density lipoprotein cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Week 16 and week 36

  106. Between group differences in low-density lipoprotein cholesterol at week 16

    Determined by an automated analyser.

    Time frame: Week 16

  107. Between group differences in low-density lipoprotein cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Week 36

  108. Changes from baseline in low-density lipoprotein cholesterol at week 16

    Determined by an automated analyser.

    Time frame: Baseline and week 16

  109. Changes from baseline in low-density lipoprotein cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Baseline and week 36

  110. Changes from week 16 in low-density lipoprotein cholesterol at week 36

    Determined by an automated analyser.

    Time frame: Week 16 and week 36

  111. Between group differences in triglycerides at week 16

    Determined by an automated analyser.

    Time frame: Week 16

  112. Between group differences in triglycerides at week 36

    Determined by an automated analyser.

    Time frame: Week 36

  113. Changes from baseline in triglycerides at week 16

    Determined by an automated analyser.

    Time frame: Baseline and week 16

  114. Changes from baseline in triglycerides at week 36

    Determined by an automated analyser.

    Time frame: Baseline and week 36

  115. Changes from week 16 in triglycerides at week 36

    Determined by an automated analyser.

    Time frame: Week 16 and week 36

  116. Between group differences in fasting glucose at week 16

    Determined by an automated analyser.

    Time frame: Week 16

  117. Between group differences in fasting glucose at week 36

    Determined by an automated analyser.

    Time frame: Week 36

  118. Changes from baseline in fasting glucose at week 16

    Determined by an automated analyser.

    Time frame: Baseline and week 16

  119. Changes from baseline in fasting glucose at week 36

    Determined by an automated analyser.

    Time frame: Baseline and week 36

  120. Changes from week 16 in fasting glucose at week 36

    Determined by an automated analyser.

    Time frame: Week 16 and week 36

  121. Between group differences in fasting insulin at week 16

    Determined by an automated analyser.

    Time frame: Week 16

  122. Between group differences in fasting insulin at week 36

    Determined by an automated analyser.

    Time frame: Week 36

  123. Change from baseline in fasting insulin at week 16

    Determined by an automated analyser.

    Time frame: Baseline and week 16

  124. Change from baseline in fasting insulin at week 36

    Determined by an automated analyser.

    Time frame: Baseline and week 36

  125. Change from week 16 in fasting insulin at week 36

    Determined by an automated analyser.

    Time frame: Week 16 and week 36

  126. Between group differences in glucose tolerance at week 16

    Determined by an oral glucose tolerance teste, analysed by an automated analyser.

    Time frame: Week 16

  127. Between group differences in glucose tolerance at week 36

    Determined by an oral glucose tolerance teste, analysed by an automated analyser.

    Time frame: Week 36

  128. Changes from baseline in glucose tolerance at week 16

    Determined by an oral glucose tolerance teste, analysed by an automated analyser.

    Time frame: Baseline and week 16

  129. Changes from baseline in glucose tolerance at week 36

    Determined by an oral glucose tolerance teste, analysed by an automated analyser.

    Time frame: Baseline and week 36

  130. Changes from week 16 in glucose tolerance at week 36

    Determined by an oral glucose tolerance teste, analysed by an automated analyser.

    Time frame: Week 16 and week 36

07

Study locations

1 site
  • University of Maia
    Maia, Porto 4476-690, Portugal
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05292261
Lead sponsor
University Institute of Maia
Collaborators
Research Center in Sports Sciences, Health Sciences and Human Development, Universidade do Porto, Laboratory of Metabolism and Exercise (LaMetEx), CIAFEL, Faculty of Sport, University of Porto, Centre of Research, Education, Innovation and Intervention in Sport, University of Porto, University of Southern Denmark, Porto Sports Medicine Center (IPDJ, IP), Gaia City Hall, Portuguese Handball Federation, European Handball Federation, São João University Hospital Centre, EPIUnit, Public Health Institute, University of Porto
Responsible party
Susana Cristina Araújo Póvoas (Associate Professor, University Institute of Maia) — Principal investigator
First posted
Mar 23, 2022
Start date
Jan 2, 2016
Primary completion
Mar 1, 2018
Completion
Mar 1, 2018
Last update
Apr 6, 2022

Study contacts

Susana Póvoas
principal investigator · University of Maia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Institute of Maia

Start the discussion